1
|
Souza SPM, Frasson FC, Takahashi MES, Duarte GBO, Castro VP, Pericole FV, Velloso LA, De Souza CA, Lorand-Metze I, Santos AO, Ramos CD. Head-to-head comparison of [ 68Ga]Ga-PSMA-11 and [ 18F]FDG PET/CT in multiple myeloma. Eur J Nucl Med Mol Imaging 2023; 50:2432-2440. [PMID: 36988710 DOI: 10.1007/s00259-023-06214-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 03/21/2023] [Indexed: 03/30/2023]
Abstract
PURPOSE The aim of this study was to compare [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT image findings in patients with multiple myeloma (MM). METHODS Twenty consecutive patients with symptomatic biopsy-proven MM were submitted to whole body [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT with a time interval of 1-8 days between procedures. All lesions were counted and had their maximum SUV (SUVmax) measured. Intra-class correlation (ICC) was used to assess the agreement between [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT findings. RESULTS A total of 266 lesions were detected in 19/20 patients. [18F]FDG detected 223/266 (84%) lesions in 17 patients and [68Ga]Ga-PSMA-11 190/266 (71%) lesions in 19 patients. Both procedures did not identify any active lesion in 1 patient. Forty-three (16%) lesions were detected only by [68Ga]Ga-PSMA-11 and 76 (29%) only by [18F]FDG. Both tracers identified 147 (55%) lesions. Intralesional mismatch of FDG-PSMA uptake was identified in 25 of these 147 lesions, found in 8 different patients. Different lesions with uptake of only [18F]FDG or [68Ga]Ga-PSMA-11 in the same patient were found in 4 patients. The highest SUVmax of [18F]FDG and [68Ga]Ga-PSMA-11 had a median (min-max) SUVmax of 6.5 (2.0-37.8) and 5.5 (1.7-51.3), respectively. [18F]FDG and [68Ga]Ga-PSMA-11 respectively identified 18 and 19 soft tissue lesions. False-positive [18F]FDG findings had minimal or no uptake of [68Ga]Ga-PSMA-11. Good reliability (ICC ≥ 0.75) was found for number of lesions, number of soft tissue lesions and highest SUVmax in each patient. CONCLUSION [18F]FDG or [68Ga]Ga-PSMA-11 alone can detect most MM lesions. Almost half of the lesions take up only one of the tracers, reflecting increased glycolysis or angiogenesis in specific lesions, and suggesting their possible complementary role in MM. The marked [68Ga]Ga-PSMA-11 uptake in some cases raises the possibility of a theranostic approach in selected patients.
Collapse
Affiliation(s)
- Stephan P M Souza
- Division of Nuclear Medicine, School of Medical Sciences University of Campinas (UNICAMP), Campinas, Brazil
| | - Fernanda C Frasson
- Division of Nuclear Medicine, School of Medical Sciences University of Campinas (UNICAMP), Campinas, Brazil
| | | | - Gislaine B O Duarte
- Center of Hematology and Hemotherapy, University of Campinas (UNICAMP), Campinas, Brazil
| | - Vania P Castro
- Division of Nuclear Medicine, School of Medical Sciences University of Campinas (UNICAMP), Campinas, Brazil
| | - Fernando V Pericole
- Center of Hematology and Hemotherapy, University of Campinas (UNICAMP), Campinas, Brazil
| | - Licio A Velloso
- Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil
- Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
| | - Carmino A De Souza
- Center of Hematology and Hemotherapy, University of Campinas (UNICAMP), Campinas, Brazil
- Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
| | - Irene Lorand-Metze
- Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
| | - Allan O Santos
- Division of Nuclear Medicine, School of Medical Sciences University of Campinas (UNICAMP), Campinas, Brazil
| | - Celso D Ramos
- Division of Nuclear Medicine, School of Medical Sciences University of Campinas (UNICAMP), Campinas, Brazil.
- Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil.
| |
Collapse
|
2
|
Pagnano KBB, Lopes ABP, Miranda EC, Duarte GO, Delamain MT, Medina SS, Pericole FV, Amarante GBD, Duarte BK, Furlin GCP, Toni IM, Paula EV, Souza CA. ESTUDO DE DESCONTINUAÇÃO DE FASE I/II DE IMATINIBE APÓS PIOGLITAZONA (EDI-PIO) EM PACIENTES COM LEUCEMIA MIELOIDE CRÔNICA EM RESPOSTA MOLECULAR PROFUNDA SUSTENTADA – ANÁLISE DE 5 ANOS DE SEGUIMENTO. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
3
|
Oliveira TC, Batista IRC, Pericole FV. PLASMOCITOMA RETROPERITONEAL GIGANTE EM PACIENTE PORTADOR DE MIELOMA MÚLTIPLO. RELATO DE CASO. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Mosci C, Pericole FV, Oliveira GB, Delamain MT, Takahashi MES, Carvalheira JBC, Etchebehere ECSC, Santos AO, Miranda ECM, Lima MCL, Amorim BJ, de Souza CA, Lorand-Metze I, Ramos CD. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. Nucl Med Commun 2020; 41:1081-1088. [PMID: 32732603 PMCID: PMC7497601 DOI: 10.1097/mnm.0000000000001259] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE F-fluorodeoxiglucose (F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging. MATERIALS AND METHODS Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded. RESULTS PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) (P = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) (P = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively (P = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive. CONCLUSION MIBI SPECT/CT performs similarly to F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a 'mismatch' pattern of FDG/MIBI uptake.
Collapse
Affiliation(s)
- Camila Mosci
- Department of Radiology, Division of Nuclear Medicine, School of Medical Sciences
| | - Fernando V Pericole
- Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP)
| | - Gislaine B Oliveira
- Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP)
| | - Marcia T Delamain
- Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP)
| | - Maria E S Takahashi
- Gleb Wataghin Physics Institute
- Post-Graduation Program in Internal Medicine, School of Medical Sciences
| | | | | | - Allan O Santos
- Department of Radiology, Division of Nuclear Medicine, School of Medical Sciences
| | - Eliana C M Miranda
- Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP)
| | - Mariana C L Lima
- Department of Radiology, Division of Nuclear Medicine, School of Medical Sciences
| | - Barbara J Amorim
- Department of Radiology, Division of Nuclear Medicine, School of Medical Sciences
| | - Carmino A de Souza
- Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP)
- Division of Hematology, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Irene Lorand-Metze
- Division of Hematology, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Celso D Ramos
- Department of Radiology, Division of Nuclear Medicine, School of Medical Sciences
- Post-Graduation Program in Internal Medicine, School of Medical Sciences
| |
Collapse
|
5
|
Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, Camacho MR, Miranda E, Lima MCL, Amorim BJ, de Souza C, Pericole FV, Lorand-Metze I, Ramos CD. Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. Sci Rep 2019; 9:16429. [PMID: 31712729 PMCID: PMC6848137 DOI: 10.1038/s41598-019-52740-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 10/21/2019] [Indexed: 12/13/2022] Open
Abstract
Many efforts have been made to standardize the interpretation of 18F-FDG PET/CT in multiple myeloma (MM) with qualitative visual analysis or with quantitative metabolic parameters using various methods for lesion segmentation of PET images. The aim of this study was to propose a quantitative method for bone and bone marrow evaluation of 18F-FDG PET/CT considering the extent and intensity of bone 18F-FDG uptake: Intensity of Bone Involvement (IBI). Whole body 18F-FDG PET/CT of 59 consecutive MM patients were evaluated. Compact bone tissue was segmented in PET images using a global threshold for HU of the registered CT image. A whole skeleton mask was created and the percentage of its volume with 18F-FDG uptake above hepatic uptake was calculated (Percentage of Bone Involvement - PBI). IBI was defined by multiplying PBI by mean SUV above hepatic uptake. IBI was compared with visual analysis performed by two experienced nuclear medicine physicians. IBI calculation was feasible in all images (range:0.00–1.35). Visual analysis categorized PET exams into three groups (negative/mild, moderate and marked bone involvement), that had different ranges of IBI (multi comparison analysis, p < 0.0001). There was an inverse correlation between the patients’ hemoglobin values and IBI (r = −0.248;p = 0.02). IBI score is an objective measure of bone and bone marrow involvement in MM, allowing the categorization of patients in different degrees of aggressiveness of the bone disease. The next step is to validate IBI in a larger group of patients, before and after treatment and in a multicentre setting.
Collapse
Affiliation(s)
- Maria E S Takahashi
- School of Medical Sciences, University of Campinas, Campinas, Brazil.,Gleb Wataghin Physics Institute, University of Campinas, Campinas, Brazil
| | - Camila Mosci
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Edna M Souza
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil.,Center of Biomedical Engineering, University of Campinas, Campinas, Brazil
| | - Sérgio Q Brunetto
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil.,Center of Biomedical Engineering, University of Campinas, Campinas, Brazil
| | - Elba Etchebehere
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Allan O Santos
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Mariana R Camacho
- School of Medical Sciences, University of Campinas, Campinas, Brazil.,Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Eliana Miranda
- Center of Hematology and Hemotherapy, University of Campinas, Campinas, Brazil
| | - Mariana C L Lima
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Barbara J Amorim
- Division of Nuclear Medicine, University of Campinas, Campinas, Brazil
| | - Carmino de Souza
- School of Medical Sciences, University of Campinas, Campinas, Brazil.,Center of Hematology and Hemotherapy, University of Campinas, Campinas, Brazil
| | - Fernando V Pericole
- Center of Hematology and Hemotherapy, University of Campinas, Campinas, Brazil
| | - Irene Lorand-Metze
- School of Medical Sciences, University of Campinas, Campinas, Brazil.,Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil
| | - Celso D Ramos
- School of Medical Sciences, University of Campinas, Campinas, Brazil. .,Division of Nuclear Medicine, University of Campinas, Campinas, Brazil.
| |
Collapse
|
6
|
Peixoto-da-Silva J, Calgarotto AK, Rocha KR, Palmeira-dos-Santos C, Smaili SS, Pereira GJ, Pericole FV, da Silva S. Duarte A, Saad ST, Bincoletto C. Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomed Pharmacother 2018; 99:237-244. [DOI: 10.1016/j.biopha.2018.01.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 12/21/2017] [Accepted: 01/03/2018] [Indexed: 12/11/2022] Open
|
7
|
Bernusso VA, Machado-Neto JA, Pericole FV, Vieira KP, Duarte AS, Traina F, Hansen MD, Olalla Saad ST, Barcellos KS. Imatinib restores VASP activity and its interaction with Zyxin in BCR–ABL leukemic cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2015; 1853:388-95. [DOI: 10.1016/j.bbamcr.2014.11.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Revised: 10/30/2014] [Accepted: 11/04/2014] [Indexed: 12/24/2022]
|